Topline data from REDEFINE 1 found CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. https: t.co JA9E3FpCsN #ObesityManagement # Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online REDEFINE 1 Trial Finds CagrilintideSemaglutide Combo Delivers Over 20% Weight Loss in Majority of Patients Applied Clinical Trials Online PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Cagrilintide Peptide Therapy: A New Era in Appetite Control and Weight Revolution Health & Wellness